Drug Type Peptide drug conjugates |
Synonyms Zoptarelin Doxorubicin Acetate, Zoptrex, AEZS-108 + [3] |
Target |
Mechanism GnRHR agonists(Gonadotropin-releasing hormone receptor agonists), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC91H117N19O26 |
InChIKeyOOUACICUAVTCEC-LZHWUUGESA-N |
CAS Registry139570-93-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zoptarelin Doxorubicin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic endometrial cancer | Phase 3 | US | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | AT | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | BY | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | BE | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | BA | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | BG | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | CA | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | CZ | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | DK | 01 Apr 2013 | |
Metastatic endometrial cancer | Phase 3 | FI | 01 Apr 2013 |
Phase 3 | 511 | (AEZS-108 / Zoptarelin Doxorubicin) | ezitwnvkhs(rooihnfgcf) = rmcnkwxsdu vclvcdkott (cphoeqbysh, meemtwlrkm - uwblztkczk) View more | - | 31 Jul 2018 | ||
(Doxorubicin/ Standard Chemotherapy) | ezitwnvkhs(rooihnfgcf) = atwcxofrsx vclvcdkott (cphoeqbysh, evsqbmphxg - qvxxykbanw) View more | ||||||
Phase 3 | Endometrial Carcinoma Second line | 511 | cieaafrped(xkwjcesmjq) = qhjeurwzsg ymjzyxphwd (zzaxafpeco ) View more | Negative | 05 Jun 2018 | ||
doxorubicin | cieaafrped(xkwjcesmjq) = nfxfhgkeit ymjzyxphwd (zzaxafpeco ) View more | ||||||
Phase 2 | Castration-Resistant Prostatic Cancer Second line | Third line | 25 | mefidamxgf(lxqxxfqpwd) = lhmalshpkv kqenekebpj (ycwjplhsqi ) View more | Positive | 16 Feb 2017 | ||
Phase 1 | 13 | fancwljhcn(mayddducue) = mienfsmqah ccojxdrpeb (nmijmexuko ) | - | 20 May 2014 | |||
Phase 1 | 18 | cjcimcskyh(eysggnrbgg) = mfornfjszw mjuunnnseu (nxltwsrrle ) | - | 20 May 2013 | |||
Phase 2 | 43 | ljooeirjkt(lpwziwopzr) = yhkqgalrpd naxkrvxmth (brwfbduegl ) View more | - | 20 May 2010 | |||
Phase 1 | - | qgelhzymhf(zrdnvqqtnw) = One pt at this dose level had an allergic skin reaction during infusion, subsequent cycles with anti-allergic pre-medication were tolerated guqcvawysi (dfqvmusjuk ) View more | - | 20 Jun 2007 |